Toll-like receptor driven B cell activation in the induction of systemic autoimmunity

NM Green, A Marshak-Rothstein - Seminars in immunology, 2011 - Elsevier
NM Green, A Marshak-Rothstein
Seminars in immunology, 2011Elsevier
Studies over the past decade have demonstrated a key role for pattern recognition receptors
in the activation of autoreactive B cells. Self reactive B cells that manage to escape negative
selection often express relatively low affinity receptors for self antigens (ignorant B cells),
and can only be activated by integrating a relatively weak BCR signal with signals from
additional receptors. Members of the toll-like receptor (TLR) gene family, and especially the
nucleic acid binding receptors TLR 7, 8 and 9, appear to play a key role in this regard and …
Studies over the past decade have demonstrated a key role for pattern recognition receptors in the activation of autoreactive B cells. Self reactive B cells that manage to escape negative selection often express relatively low affinity receptors for self antigens (ignorant B cells), and can only be activated by integrating a relatively weak BCR signal with signals from additional receptors. Members of the toll-like receptor (TLR) gene family, and especially the nucleic acid binding receptors TLR 7, 8 and 9, appear to play a key role in this regard and promote the production of autoantibodies reactive with DNA- or RNA-associated autoantigens. These autoantibodies are able to form immune complexes with soluble or cell-bound ligands, and these immune complexes can in turn activate a second round of proinflammatory cells that further contribute to the autoimmune disease process. Recent data have emerged showing a pathogenic role for TLR7, with an opposing, protective role for TLR9. Targeting these disregulated pathways offers a therapeutic opportunity to treat autoimmune diseases without crippling the entire immune system. Further understanding of the role of specific receptors, cell subsets, and inhibitory signals that govern these TLR-associated pathways will enable future therapeutics to be tailored to specific categories of autoimmune disease.
Elsevier